Delivery Order SPE2DB24D2100-SPE2DB25FBFXM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,931.20 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order carries no set-aside designation and was competitively awarded under an existing Indefinite Delivery Contract (IDC). The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,515.37 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages). This competitively awarded, firm fixed-price contract was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,431.30 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages). This contract, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,827.12 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract. The delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-competitive, competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $97,535.14 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). This firm fixed-price contract, awarded on July 31, 2025, with completion targeted for August 1, 2025, represents a non-competitive set-aside delivery order issued under DLA's pharmaceutical procurement framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,023.70 on August 8, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The delivery order is scheduled for completion by August 11, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Eliquis 5 mg tablets (60-count units) at a firm fixed price ceiling value of $25,069.77. This non-set-aside, competitively awarded contract is scheduled for completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count) with a ceiling value of $5,382.14. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract has a ceiling value of $6,349.14 and carries no set-aside designation. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFXMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count packages) with a ceiling value of $4,039.17. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, issued on August 19, 2025. The contract is non-set-aside and was competitively awarded. AmerisourceBergen's place of performance is listed as its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026. As a prime pharmaceutical vendor to the federal government, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The Eliquis order supports the DLA's medical supply chain requirements for anticoagulant medications used across Defense Health Agency, U.S. Coast Guard, and other federal healthcare beneficiaries. The company's extensive pharmaceutical portfolio and proven capability to meet federal procurement standards through open competition demonstrate its role as a critical vendor for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/19/25 |